A Phase 3 pivotal trial of GB-102 in patients with Wet-age-related-macular-degeneration
Latest Information Update: 13 Apr 2023
At a glance
- Drugs Sunitinib (Primary)
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Sponsors CalciMedica; GrayBug inc.
- 20 Mar 2023 According to a CalciMedica media release, GrayBug has merger with CalciMedica and the combined company is named as CalciMedica.
- 26 Nov 2020 New trial record
- 12 Nov 2020 According to a Graybug Vision media release, it plans to Initiate two pivotal GB-102 Phase 3 trials in patients with wet AMD in the second half of 2021.